MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial
AuthorsLevine, A. Joan
Haile, Robert W.
Ahnen, Dennis J.
Cole, Bernard F.
Barry, Elizabeth L.
Ali, Iqbal U.
Ueland, Per M.
Baron, John A.
UMass Chan AffiliationsDepartment of Molecular Genetics and Microbiology
Graduate School of Biomedical Sciences
KeywordsAdenoma; Alleles; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Double-Blind Method; Female; Folic Acid; Genotype; Humans; Linear Models; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Recurrence, Local; Placebos; Polymorphism, Genetic
Medicine and Health Sciences
MetadataShow full item record
AbstractMethylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism. We assessed the association between two common MTHFR variants, 677C>T and 1298A>C, and adenoma recurrence in the context of a randomized double- blind clinical trial of aspirin use and folate supplementation. We used generalized linear regression to estimate risk ratios and 95% confidence intervals (95% CI) for recurrence, adjusting for age, sex, clinical center, follow-up time, and treatment status. Neither MTHFR polymorphism was associated with overall or advanced adenoma recurrence. Compared with those with two wild-type alleles, the relative risk for advanced adenoma was 0.75 (95% CI, 0.36-1.55) for the MTHFR 677 TT genotype and 1.16 (95% CI, 0.58-2.33) for the MTHFR 1298 CC genotype. The effect of folate supplementation on recurrence risk did not differ by genotype. Our findings indicate that the MTHFR genotype does not change adenoma risk in a manner similar to its effect on colorectal cancer, and does not modify the effect of folate supplementation on metachronous adenoma risk.
SourceCancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2409-15. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/33005
PubMed ID18768511; 18768511
Related ResourcesLink to Article in PubMed